Related references
Note: Only part of the references are listed.Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy
Jia Wei et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway
Lehe Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer
Shengling Fu et al.
CANCER LETTERS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling
Hailun Zheng et al.
MOLECULAR CARCINOGENESIS (2019)
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Ioanna Keklikoglou et al.
NATURE CELL BIOLOGY (2019)
Targeting colon cancer with the novel STAT3 inhibitor bruceantinol
Ning Wei et al.
ONCOGENE (2019)
Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map
Jennifer Huynh et al.
NATURE REVIEWS CANCER (2019)
Selective Autophagy Regulates Cell Cycle in Cancer Therapy
Kai Zheng et al.
THERANOSTICS (2019)
Colorectal Cancer Screening for Average-Risk Adults: 2018 Guideline Update From the American Cancer Society
Andrew M. D. Wolf et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer
Yoon-Jae Kim et al.
CANCER LETTERS (2018)
Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
Eunhye Oh et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide
Lu Lu et al.
ONCOGENE (2018)
Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Jenny D. Beebe et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy and Sensitizes Cancer Cells to Chemotherapy
Pei-Feng Liu et al.
THERANOSTICS (2018)
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer
Hong Zhu et al.
THERANOSTICS (2018)
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
Zhi Huang et al.
THERANOSTICS (2018)
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
T. Zhang et al.
ONCOGENE (2017)
STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer
Wei-Ying Kuo et al.
THERANOSTICS (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential
Santosh Chauhan et al.
NATURE COMMUNICATIONS (2015)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Paul A. Spagnuolo et al.
BLOOD (2010)
Share Paper
